Interferon-α plus lamivudine<i>vs</i>lamivudine reduces breakthroughs, but does not affect sustained response in HBeAg negative chronic hepatitis B

Abstract

Our results demonstrate that IFN-alpha plus lamivudine combination therapy did not increase the sustained response, compared to lamivudine. However, combination therapy reduces the likelihood of VBR due to YMDD mutants and prolongs the time period until the breakthrough development.